Pascal Dabel, MD
Nephrology · Mission Hills, CANPI 1033306592
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 224 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations.
Across 224 payments — averaging $22.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$849
- GSK$560
- Aurinia Pharma U.S., Inc.$461
- Otsuka America Pharmaceutical, Inc.$385
- Vifor Pharma, Inc.$362
- plus $1K from 21 others
Across 91 payments — averaging $13,007 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$398K
- GSK$316K
- Cleerly, Inc.$120K
- Travere Therapeutics, Inc.$96K
- Vertex$78K
- Pfizer$71K
- plus $105K from 3 others
What the payments were for
- Food & beverage$4,80297%
- Education$1633%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 50 | $1,051 |
| Amgen(2 entities) | 49 | $849 |
| GSK | 24 | $560 |
| Aurinia Pharma U.S., Inc. | 19 | $461 |
| Otsuka America Pharmaceutical, Inc. | 14 | $385 |
| Vifor Pharma, Inc. | 17 | $362 |
| Novartis | 8 | $185 |
| Akebia Therapeutics Inc | 7 | $158 |
| Veloxis Pharmaceuticals, Inc. | 2 | $101 |
| Henry Schein, Inc. | 2 | $88 |
| OPKO Pharmaceuticals, LLC | 4 | $88 |
| Travere Therapeutics, Inc. | 3 | $87 |
| Fresenius USA Marketing, Inc. | 4 | $77 |
| Boehringer Ingelheim | 3 | $71 |
| Calliditas Therapeutics US Inc. | 3 | $71 |
| Nxstage Medical, Inc. | 1 | $45 |
| Sanofi | 3 | $43 |
| Ultragenyx Pharmaceutical Inc. | 2 | $36 |
| Mallinckrodt Hospital Products Inc. | 1 | $35 |
| Lilly USA, LLC | 1 | $32 |
| Mallinckrodt Enterprises LLC | 1 | $31 |
| Bayer | 1 | $31 |
| Ascendis Pharma Endocrinology Inc | 1 | $28 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Ardelyx, Inc. | 1 | $26 |
| Rockwell Medical, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
How this compares
$4,965 in reported general payments places this provider in the 75th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 18 | $47,175 |
| FarxigaDapagliflozin Propanediol | 32 | $37,105 |
| LokelmaSodium Zirconium Cyclosilicate | 24 | $29,372 |
| JardianceEmpagliflozin | 17 | $16,577 |
| EpogenEpoetin Alfa | 16 | $10,139 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $8,816 |
| Febuxostat | 32 | $4,698 |
| Calcium Acetate | 20 | $1,547 |
| Bumetanide | 32 | $1,201 |
| Losartan Potassium | 73 | $1,053 |
| Nifedipine ErNifedipine | 28 | $982 |
| Sevelamer Carbonate | 15 | $977 |
| Allopurinol | 81 | $785 |
| Tamsulosin Hcl | 35 | $730 |
| Furosemide | 142 | $727 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,051 | $66,47856 claims |
| Fresenius USA Marketing, Inc.Velphoro | $77 | $47,17518 claims |
| Boehringer IngelheimJardiance | $71 | $16,57717 claims |
| AmgenEpogen | $849 | $10,13916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,341 nephrology providers in California.
Other nephrology in Mission Hills
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.